Cited by 197Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver Diseases and Immunity

The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Open access

Petta, Salvatore, Sebastiani, Giada, Viganò, Mauro, Ampuero, Javier, Wai-Sun Wong, Vincent, Boursier, Jerome, Berzigotti, Annalisa, Bugianesi, Elisabetta, Fracanzani, Anna Ludovica, Cammà, Calogero, Enea, Marco, Grottes, Marraud des, Di Marco, Vito, Younes, Ramy, Keyrouz, Aline, Mazzola, Sergio, Mendoza, Yuly, Pennisi, Grazia, Romero-Gomez, Manuel, Craxì, Antonio, de Ledinghen, Victor·2021·Clinical Gastroenterology and Hepatology

DOI 10.1016/j.cgh.2020.06.045

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.Methods We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3-F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19-63 months).Results Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02-1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00-1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02-1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05-2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01-3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11-2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10-3.38; P = .02).Conclusions In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2020.06.045

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046

Show all 34 references

Research works printed but not linked: 5

Shili-Masmoudi, 2020, Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease, Liver Int, 40, 581, 10.1111/liv.14301 · DOI
2000, American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report, Diabetes Care, 23, S4
de Franchis, 2015, Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension, J Hepatol, 63, 743, 10.1016/j.jhep.2015.05.022 · DOI · Paper page
Cillo, 2015, A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model", Am J Transplant, 15, 2552, 10.1111/ajt.13408 · DOI
Boursier, 2013, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, 57, 1182, 10.1002/hep.25993 · DOI · Paper page

Sorted by citations

Items 101–196 of 196

Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review
Tun, K. M., Noureddin, N., & Noureddin, M. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000066 · Cited by 8
Liver stiffness is associated with all‐cause mortality in patients with NAFLD : A systematic review and meta‐analysis
Ciardullo, S., Muraca, E., Zerbini, F., & Perseghin, G. (2023) · Liver International · doi:10.1111/liv.15742 · Cited by 8
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
The role of liver and spleen elastography in advanced chronic liver disease
Dajti, E., Marasco, G., Ravaioli, F., Alemanni, L. V., Rossini, B., Colecchia, L., Vestito, A., Festi, D., & Colecchia, A. (2021) · Minerva Gastroenterology · doi:10.23736/s2724-5985.20.02793-2 · Cited by 8
Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease
Rigor, J., MARTINS, M. E., Passos, B., Oliveira, R., & Martins‐Mendes, D. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09290-5 · Cited by 7
Significant Within-Individual Variability in VCTE Liver Stiffness Measurements at Two Intercostal Spaces in Subjects with MASLD: Implications for Evaluating Improvement in Liver Fibrosis After Weight-Loss or Liver-Directed Therapy
Woodard, J. S., Velji-Ibrahim, J., & Abrams, G. A. (2024) · Diseases · doi:10.3390/diseases12110288 · Cited by 8
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 11
Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease
Jiang, H., Yu, H., Hu, C., Huang, Y., Yang, B., Xi, X., Lei, Y., Wu, B., & Yang, Y. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101788 · Cited by 7
FGF2 Mediated USP42‐PPARγ Axis Activation Ameliorates Liver Oxidative Damage and Promotes Regeneration
Yang, N., Tian, Q., Lei, Z., Wang, S., Cheng, N., Wang, Z., Jiang, X., Zheng, X., Xu, W., Ye, M., et al. (2025) · Advanced Science · doi:10.1002/advs.202408724 · Cited by 8
Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement
Cerrito, L., Mignini, I., Ainora, M. E., Mosoni, C., Gasbarrini, A., & Zocco, M. A. (2023) · Cancers · doi:10.3390/cancers15030637 · Cited by 7
Point Shear-Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver-Related Events in Patients With Chronic Viral Hepatitis
Sampere, L. H., Vermehren, J., Mücke, V. T., Graf, C., Peiffer, K., Dultz, G., Zeuzem, S., Waidmann, O., Filmann, N., Bojunga, J., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1623 · Cited by 7
Liver stiffness measurements in patients with metabolic dysfunction-associated steatotic liver disease: Updates on the method effectiveness and perspectives
Sukocheva, O. A., Ow, T., Harding, D., Mire, M. L., & Tse, E. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106675 · Cited by 6
Ultrasound Elastography—Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment
Hari, A. (2021) · Medicina · doi:10.3390/medicina57060516 · Cited by 6
Using Blue Mini-LEDs as a Light Source Designed a Miniaturized Optomechanical Device for the Detection of Direct Bilirubin
Ye, Z. T., Kuo, H.-C., Tseng, S. F., Chung, S.-R., & Tsou, S. X. (2022) · Nanoscale Research Letters · doi:10.1186/s11671-022-03750-z · Cited by 6
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease
Maiorana, F., Neschuk, M., Caronia, M. V., Elizondo, K., Schneider, A., Veron, G., Zapata, P. D., & Barreyro, F. J. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101541 · Cited by 6
Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.11.001 · Cited by 6
PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development
Son, H., Koo, B. K., Joo, S. K., Lee, D. H., Jang, H., Park, J. H., Chang, M. S., & Kim, W. K. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.02.024 · Cited by 6
Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort
Cinque, F., Saeed, S., Kablawi, D., Ballesteros, L. R., Elgretli, W., Moodie, E. E. M., Price, C. E., Monteith, K., Cooper, C., Walmsley, S. L., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076547 · Cited by 7
Mortality and Cardiovascular Outcomes in Patients with MAFLD Compared with Patients with MASLD: A Systematic Review and Meta-Analysis
Yang, J., Kim, Y. R., Na, S. K., Kim, S., An, J., & Shim, J. H. (2025) · Gut and Liver · doi:10.5009/gnl250275 · Cited by 5
Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality
Diambra, L. A., Sookoian, S. C., & Pirola, C. J. (2026) · Gut · doi:10.1136/gutjnl-2026-338674 · Cited by 4
Surveillance for patients at risk of hepatocellular carcinoma: how to improve its cost-effectiveness and expand the role of multidisciplinary tumor board?
Lani, L., Zaccherini, G., Giannini, E. G., & Trevisani, F. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2024.136 · Cited by 5
The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
Machado, M. V. (2023) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000531397 · Cited by 6
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis
Fan, H. X., Liu, Z., Zhang, P., Wu, S. L., Han, X., Huang, Y., Zhu, Y., Chen, X., & Zhang, T. (2023) · Hepatology International · doi:10.1007/s12072-023-10512-1 · Cited by 5
Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction
Rowe, I. A. C., & D’Amico, G. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.038 · Cited by 5
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 6
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial
Chalasani, N., Vuppalanchi, R., Noureddin, M., Shiffman, M. L., Lawitz, E., Mena, E., Gunn, N., de Guevara, L. L., Elgouhari, H. M., Safadi, R., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001774 · Cited by 4
Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
Macı́as, J., Frías, M., Pineda, J. A., Corona‐Mata, D., Corma‐Gómez, A., Rivero‐Juárez, A., Santos, M. L., Deltoro, M. G., Rivero, A., Ricart-Olmos, C., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18413 · Cited by 4
Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 4
Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease
Blank, V., Petroff, D., Boehlig, A., Heinze, A., Karlas, T., Berg, T., & Wiegand, J. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002347 · Cited by 4
Preparation of Nano-microbubbles and Curative Effect of 125I Particles for Primary Liver Cancer Guided by Abdominal Interventional Ultrasound
Chen, Y., Gao, S., Jin, Y., & Wang, X. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.3.16 · Cited by 4
Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease
Liguori, A., Zoncapè, M., & Tsochatzis, E. A. (2022) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2022.8718/2022 · Cited by 4
Impact of 20% Change in Vibration-Controlled Transient Elastography-Measured Liver Stiffness on Liver-Related Outcomes: A Systematic Review and Meta-Analysis
Ouranos, K., Michael, M., Mylona, E. K., Shehadeh, F., Kalligeros, M., Teng, M. L. P., Muthiah, M. D., Siddiqui, M. S., Kodali, S., Basra, T., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.12.021 · Cited by 3
HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients
Țâru, M.-G., Stefanini, B., Boe, M., Capelli, R., Chen, R., Abbati, C., Santangeli, E., Salamone, A., Girolami, F., Tovoli, F., et al. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s561956 · Cited by 3
One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Pennisi, G., Infantino, G., Maria, G. D., Tsochatzis, E. A., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., Boursier, J., Calleja, J. L., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.020 · Cited by 3
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
Cobbold, J. F., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E. D., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 3
Novel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
Amato, F., Marano, M., Gjini, K., VAIRA, L., Bugianesi, E., & Armandi, A. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03186-9 · Cited by 4
Transient elastography can stratify patients with Child Pugh A cirrhosis according to long-term risk of decompensation: a longitudinal cohort study
Armstrong, P. R., Moriarty, A., Dillon, A., Galvin, Z., Russell, J. L., & Stewart, S. F. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003045 · Cited by 3
Prognostic value of non‐invasive scores based on liver stiffness measurement, spleen diameter and platelets in HIV ‐infected patients
Benmassaoud, A., Macı́as, J., Delamarre, A., Corma‐Gómez, A., Guaraldi, G., Milić, J., Rockstroh, J. K., van Bremen, K., Tsochatzis, E. A., Mulay, A., et al. (2023) · Liver International · doi:10.1111/liv.15605 · Cited by 3
Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents
Elbahrawy, A., Atalla, H., Mahmoud, A. A., Eliwa, A., Alsawak, A., Alboraie, M. A. A., Madian, A., Alashker, A., Mostafa, S., Alwassief, A., et al. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1227317 · Cited by 3
Does NAFLD Fibrosis Score predict mortality risk among MAFLD patients?: a systematic review and meta-analysis
Rahadini, A. A. D., & Rahadina, A. (2021) · Bali Medical Journal · doi:10.15562/bmj.v10i2.2359 · Cited by 3
Prognostication in Advanced Chronic Liver Disease Using Liver Stiffness Measurement: Repetita Iuvant
Ampuero, J., & Berzigotti, A. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.08.001 · Cited by 3
Can liver stiffness measurement accurately predict disease progression and clinical outcome in patients with metabolic dysfunction-associated steatotic liver disease and bridging fibrosis or cirrhosis?
van Doorn, D. J., Holleboom, A. G., Takkenberg, R. B., Verheij, J., & Lantinga, M. A. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-445 · Cited by 2
FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists
van Beurden, W., Mendoza, Y. P., Lange, N. F., Bosch, J., Berzigotti, A., & Rodrigues, S. G. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108978 · Cited by 2
Monitoring Liver and Spleen Stiffness Changes May Predict Clinical Response to Non-selective B-Blockers in Portal Hypertension: A Systematic Review and Meta-Analysis
Tambaki, M., Neonaki, A., Lekakis, V., Papatheodoridi, Μ., & Karagiannakis, D. S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09304-4 · Cited by 2
The Portal Hypertension Decompensation Score: A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension
Jeffrey, A. W., Majumdar, A., Jeffrey, G. P., Bertot, L. C., Wallace, M., Mitchell, T., Huang, Y., Joseph, J., Garas, G., Cheng, W., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003744 · Cited by 2
What Can We Learn From Longitudinal Measurements of Liver Stiffness in Metabolic Dysfunction‐Associated Steatotic Liver Disease?
André‐Dumont, S., & Lanthier, N. (2026) · Liver International · doi:10.1111/liv.70680 · Cited by 2
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns
Venkatakrishnan, A., Purushotham, K., Varma, G., Aman, A., Murugadoss, K., & Soundararajan, V. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00076-w · Cited by 2
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
Curry, M. P., Tam, E., Schneider, C., Abdelgelil, N., Hassanien, T., & Afdhal, N. H. (2024) · International Journal of Hepatology · doi:10.1155/2024/8877130 · Cited by 2
Prognostic value of changes in vibration‐controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease: The Rio de Janeiro type 2 diabetes cohort
Leite, N. C., Villela‐Nogueira, C. A., Santos, L. V., Cardoso, C. R. L., & Salles, G. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16195 · Cited by 2
A Liver Stiffness Measurement-Based Nomogram Predicts Variceal Rebleeding in Hepatitis B-Related Cirrhosis
Liu, L., Liu, Q., Xiao, N., Zhang, Y., Nie, Y., & Zhu, X. (2022) · Disease Markers · doi:10.1155/2022/4107877 · Cited by 2
Heterogeneity in the risk of incident liver cirrhosis driven by PNPLA3 genotype and diabetes among different populations
Koo, B. K., Lee, D. H., Park, J. H., & Kim, W. K. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-624 · Cited by 2
Correlated factors and prognostic importance of reduction in liver stiffness measurement in individuals with type 2 diabetes and MASLD
Cardoso, C. R. L., Villela‐Nogueira, C. A., Salles, G. F., & Leite, N. C. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104478 · Cited by 1
Longitudinal changes in vibration‐controlled transient elastography in pediatric fatty liver disease
Sweeny, K. F., Aguilera‐Rico, C., Chan, C., Liu, E., & Lee, C. K. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70380 · Cited by 1
Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes
Bril, F., Huynh, K., & Bolla, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0762 · Cited by 2
Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in metabolic dysfunction–associated steatohepatitis (MASH)
Sanyal, A. J., Abdelmalek, M. F., & Loomba, R. S. (2026) · Hepatology · doi:10.1097/hep.0000000000001734 · Cited by 1
Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review
Payancé, A., Rautou, P., Boursier, J., Castéra, L., Valla, D. C., & Elkrief, L. (2026) · Liver International · doi:10.1111/liv.70627 · Cited by 1
Longitudinal Validation of Clinical Care Pathways for Metabolic Dysfunction–Associated Steatotic Liver Disease in a Prospective Cohort of Individuals With Type 2 Diabetes
Dounel, J., Díaz, L. A., Bettencourt, R., Tavaglione, F., Madamba, E. V., Richards, L., Loomba, R. S., & Ajmera, V. H. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101022 · Cited by 1
Threshold‐Defined Liver Stiffness Trajectories and Liver‐Related Event Risk in Chronic Liver Disease: A Cohort Study
Kim, D. Y., Lee, J. S., Lee, H. W., Kim, M. N., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2026) · Liver International · doi:10.1111/liv.70819 · Cited by 1
ALPS ‐ HCC Score: A Dynamic Liver Stiffness Measurement‐Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma
Huang, Y., Yu, H., Yang, B., Jiang, H., Hu, C., Yu, Q., Xi, X., Li, M., Lei, Y., Wu, B., et al. (2026) · Liver International · doi:10.1111/liv.70866 · Cited by 1
Liver Elastography for Prognostication and Monitoring Patients With Compensated Advanced Chronic Liver Disease
Thiele, M. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_11 · Cited by 1
Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.11.010 · Cited by 1
Esteatosis hepática metabólica
Iruzubieta, P., Arias, M., Barrio, M. D., Echavaría, V., Alonso‐Peña, M., & Crespo, J. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.03.012 · Cited by 2
Abbreviated Multiparametric MR Solution (the “Liver Triple Screen”), the Future of Non-Invasive MR Quantification of Liver Fat, Iron, and Fibrosis
Low, G., Chee, R. K. W., Wong, Y. J., Tandon, P., Manolea, F., Locas, S., Ferguson, C., Tu, W., & Wilson, M. P. (2024) · Diagnostics · doi:10.3390/diagnostics14212373 · Cited by 1
Prevalence and associated factors of MAFLD in adults with type 2 diabetes
He, Y., Xiao, F., Yi, B., & Lu, J. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003572 · Cited by 1
Disease-specific non-invasive assessment of liver fibrosis and portal hypertension
Cavoli, T. V. L., Curto, A., Lynch, E. N., Galli, A., & Milani, S. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.25.03845-8 · Cited by 1
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity
Kim, W. (2021) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.16641 · Cited by 1
Reply
Bassegoda, O., Olivas, P., Graupera, I., & Hernández–Gea, V. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.040 · Cited by 1
The Role of Transient Elastography in NAFLD
Pennisi, G., Giammanco, A., & Petta, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-74132-7_5
Higher Liver Stiffness Predicting Adverse Outcomes in Cirrhotic Patients with Child-Pugh Grades A and B
Chunlei, L., Qian, Y., Qu, Y., Wang, L., Jiaye, L., & Li, T. (2021) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2021.10.1168
Issue Highlights
Singh, S. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.001
Surgical Management of Hepatocellular Carcinoma
Pagano, D., Mamone, G., Calamia, S., & Gruttadauria, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_7-1
Magnetic Resonance Elastography as a Predictor of Response to Therapy in Patients With Nonalcoholic Steatohepatitis.
Noureddin, M. (2021) · PubMed Central
Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study
Mangia, A., Piazzolla, V., Squillante, M. M., Cocomazzi, G., Valori, V. M., Copetti, M., Parente, P., Attino, V., & Guido, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195969
Surgical Management of Hepatocellular Carcinoma
Pagano, D., Mamone, G., Calamia, S., & Gruttadauria, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_7
Evaluation of the Effect of CSPH, Reduction of HVPG, and Other Factors Predicting the First Decompensation in Cirrhosis
Tripathi, D., Villanueva, C., & Bosch, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_35
Noninvasive assessment of liver disease severity: image-related
Teh, K. K., Chang, J. P., & Goh, G. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00014-8
Rapport 23-02. Le foie stéatosique non alcoolique : un défi de santé publique
Brissot, P., & Buffet, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.014
Prevalencia, severidad y costes asociados al diagnóstico de pacientes con esteatosis hepática metabólica (EHmet)
Cuadrado, N. M. (2021) · doi:10.35376/10324/59897
Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Mu, Y., Peng, C., Chang, H., Wang, S., & Zuo, X. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10353/2024
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
Yu, J. H. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.5.232
Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
Chun, H. S., Lee, M., & Kim, T. H. (2024) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2024.12.3.184
Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging
Kalafateli, M., Aydin, B. S., Polat, B., Yee, M. S., Forlano, R., Izzi‐Engbeaya, C. N., Thursz, M. R., Mullish, B. H., & Manousou, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102705 · Cited by 1
Diagnostic accuracy of predictive indices for assessing liver steatosis and fibrosis as compared to transient elastography in patients with non-alcoholic fatty liver disease
Brekhunets, R. M., Андреев, Д. Н., Maev, I. V., Dicheva, D. T., & Киримовна, К. А. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-225
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Prognostic Scores in the Management of MASH Related Cirrhosis
Jeffrey, A. W., Adams, L. A., Chen, J., Attree, C., Majumdar, A., & Bertot, L. C. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00698-3
Evaluation of Liver Stiffness in Obesity: A Comparison of Canon Aplio i800 2d-Shear Wave Elastography and Siemens Sequoia Point Shear Wave Elastography
Kapoor, A., & Kapur, A. (2025) · International Journal of Gastroenterology · doi:10.11648/j.ijg.20250901.110
MASLD-Related HCC: Trends, Pathogenesis and Current Treatment Options
Li, F., & Wu, Y. (2025) · Advances in Precision Medicine · doi:10.18063/apm.v10i2.896
Hepatocellular Carcinoma in the Setting of Metabolic Dysfunction Associated Steatotic Liver Disease
Su, A., Clark, J. M., & Kim, A. K. (2026) · Current Hepatology Reports · doi:10.1007/s11901-025-00707-5
Rationale Diagnostik bei metabolischen Lebererkrankungen (MASLD)
Barton, A., & Schattenberg, J. M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01456-9
Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future
Zeng, R., Shao, Y. C., Lin, R.-T., Shen, X.-T., Sun, Q., Xin, X., Liu, P., Fan, J., Hu, Y., & Feng, Q. (2026) · Liver International · doi:10.1111/liv.70784
Non-invasive Tests for the Prediction of Liver-related Events in Patients with MASLD: A Systematic Review and Meta-analysis
Wang, X. W., Dong, X., 钱洛丹, Yang, Z., Yang, D., & Niu, Y. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.06.068
Metabolic dysfunction–associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Liver stiffness dynamics in European populations
André‐Dumont, S., & Lanthier, N. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00188-3
Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH
Loomba, R. S., Chen, R., Wang, Y., Bettencourt, R., Madamba, E. V., Tesfai, K., Richards, L., Muthiah, M. D., Tan, E., Young, D. Y., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001856 · Cited by 1
Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges
Lee, H. W., Díaz, L. A., Wong, V. W., & Chan, W. (2026) · Hepatology International · doi:10.1007/s12072-026-11148-7
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31

Authors: Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., Enea, M., Grottes, M. D., Di Marco, V., Younes, R., Keyrouz, A., Mazzola, S., Mendoza, Y., Pennisi, G., Romero-Gomez, M., Craxì, A., & de Ledinghen, V.
Affiliations: University of Palermo (IT)
McGill University Health Centre (CA)
University of Milan (IT)
Instituto de Biomedicina de Sevilla (ES)
University of Bern (CH)
University of Turin (IT)
Inserm (FR)
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
Corresponding author: Petta, Salvatore
ORCID: Petta, Salvatore
Sebastiani, Giada
Viganò, Mauro
Ampuero, Javier
Berzigotti, Annalisa
Bugianesi, Elisabetta
Fracanzani, Anna Ludovica
Cammà, Calogero
Enea, Marco
Younes, Ramy
Mazzola, Sergio
Mendoza, Yuly
Pennisi, Grazia
Venue: Clinical Gastroenterology and Hepatology
Publisher: Elsevier BV
Published: 2021-04
Volume: 19
Issue: 4
Pages: 806-815.e5
ISSN: 1542-3565 (ISSN-L)
DOI: 10.1016/j.cgh.2020.06.045
OpenAlex: W3038330698
Cited by: 197
References: 34
Citations by year: 2026: 26 · 2025: 32 · 2024: 45 · 2023: 38 · 2022: 27 · 2021: 25
FWCI: 16.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Clinical Gastroenterology and Hepatology (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
HAL (submittedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
BORIS (University Library Bern) (submittedVersion, other-oa)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Open Access CRIS of the University of Bern
Funders: Fonds de Recherche du Québec - Santé (267806, 27127)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, compensated advanced chronic liver disease, liver stiffness, transient elastography, liver fibrosis, hepatic decompensation, hepatocellular carcinoma, liver-related mortality, extrahepatic complications, liver-related events, risk stratification, variceal bleeding, ascites, encephalopathy
MeSH terms: Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Retrospective Studies, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks